|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| Prolonging PSA Progression-Free Survival with Intensification of ADT, the PRESTO Study (AFT19)
|
Rahul Aggarwal, MD
In this conversation, Rahul and Charles Ryan discuss the AFT-19, PRESTO study of androgen annihilation in high-risk biochemically relapsed prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
| Timing and Intensity of ADT in Biochemical Recurrence
|
Channing J. Paller, MD
Channing Paller joins Alicia Morgans at ASCO 2022 to discuss considerations in the timing and intensity of ADT in biochemical recurrence. Dr. Paller gives an overview of her presentation and the two explore important considerations when timing treatment for prostate cancer after recurrence and relevant clinical trial data, such as TOAD and CRUK.
|
|
|
|
|
|
|
|
|
|
|
| Systemic Treatment in the Context of Salvage Radiation and Biochemical Recurrence
|
Piet Ost, MD
Piet Ost joins Alicia Morgans in a broad topic of discussion on biochemical recurrence, focusing on systemic treatment in the context of salvage radiation and biochemical recurrence. They discuss when to add androgen deprivation therapy and for what period of time as well as moving beyond PSA to understand risk stratification. Dr. Ost is looking forward to seeing more data from molecular studies such as the molecular subset from Decipher to help characterize these patients.
|
|
|
|
|
|
|
|
|
|
|
| Systemic Therapy in Patients with a Biochemical Recurrence in Prostate Cancer in Latin America
|
Fabio Shultz, MD
Phillip Koo is joined by Fabio Schutz at the 13th International Uro-Oncology Conference in São Paulo, Brazil in a discussion highlighting hormonal blockade and biochemical recurrence as well as targets and biomarkers in advanced prostate cancer. Dr. Schutz brings attention to the lack of accessible genetic testing in Brazil and Latin America.
|
|
|
|
|
|
|
|
|
|
|
| PRESTO: A Phase 3, Open-Label Study of Androgen Annihilation in Patients with High-Risk Biochemically Relapsed Prostate Cancer (AFT-19) |
| Rahul Aggarwal, MD |
| Rahul Aggarwal discusses PRESTO, a phase 3, open-label study of androgen annihilation in patients with high-risk biochemically relapsed prostate cancer. More complete androgen receptor blockade with apalutamide in addition to ADT prolongs biochemical progression-free survival with a manageable safety profile, without impacting time to testosterone recovery following a finite duration of treatment. |
|
|
|
|
|
|
|
|
|
|
| Discussion of PRESTO in High-Risk Biochemically Relapsed Prostate Cancer and PROpel in mCRPC |
| Johann de Bono, MD, MSc, PhD, FRCP, FMedSci |
| Johann De Bono discusses two key studies including “PRESTO: A Phase 3, Open-Label Study of Androgen Annihilation in Patients with High-Risk Biochemically Relapsed Prostate Cancer (AFT-19)” presented by Dr. Rahul Aggarwal and “Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone and olaparib vs abiraterone and placebo as first-line therapy for patients with mCRPC” presented by Dr. Fred Saad. |
|
|
|
|
|
| Reimaging the Timing and Intensity of ADT in Biochemical Recurrence |
| Channing J. Paller, MD |
| In this presentation, Channing Paller discusses questions related to the timing and intensity of androgen deprivation therapy (ADT) in biochemical recurrence of prostate cancer. Dr. Paller noted that biochemical recurrence is common. While PSA is critical for diagnosing BCR, it should not be the only factor considered in determining treatment approach. The risks and benefits of treatment should be considered when initiating ADT. |
|
|
|
|
|
| Impact of 18F-Fluciclovine PET/CT on Plans for ADT in Patients with Biochemical Recurrence of Prostate Cancer: Data Analysis from two Prospective Trials |
| Gerald L. Andriole, Jr, MD |
| Gerald Andriole discusses the impact of 18F-fluciclovine PET/CT on plans for ADT in patients with biochemical recurrence of prostate cancer. Despite improvements in early detection and primary therapy, biochemical recurrence of prostate cancer after curative-intent primary therapy remains common. |
|
|
|
|
|
 |
